本頁只刊出中文翻譯與中文說明；英文原文請見下方原文連結。
原文連結
論文資訊
- 類型：已發表論文
- 日期：2025-01-18
摘要
Policy Points Cell and gene therapies (CGTs) offer treatment for rare and oftentimes deadly 疾病, but their prices are high, and payers may seek to limit spending. Total annual costs of covering all existing and expected CGTs for the entire US 族群 2023-2035 to amount to less than $20 per person and concentrate in commercial and state Medicaid plans. Reinsurance fees add to expected costs. Policies that improve coverage and affordability are needed to assure patient access to CGTs.ContextCell and gene therapies (CGTs) offer treatment to rare and oftentimes deadly 疾病s. Because of their high price and uncertain clinical outcomes, US insurers commonly restrain patient access to CGTs, and these barriers may create or perpetuate existing disparities. A reconsideration of existing insurance policies
※ 此為已發表論文，全文需透過期刊付費取得